Overview
Isoniazid preventive therapy (IPT) is used to reduce the incidence of active tuberculosis (TB) in specific populations. While IPT has shown efficacy in reducing active TB, its impact on all-cause mortality and the risk of specific adverse events requires careful consideration.Diagnosis
No diagnostic criteria for isoniazid-resistant TB were provided in the abstracts.Management
Isoniazid preventive therapy (IPT) reduces the incidence of active TB 1.
IPT did not demonstrate a reduction in all-cause mortality in people living with HIV (PWH) 1.
The risk of peripheral neuropathy associated with IPT was not significantly increased 1.
The risk of hepatotoxicity associated with IPT was not significantly increased 1.Special Populations
In people living with HIV (PWH), IPT significantly reduced the incidence of active TB 1.Key Recommendations
Isoniazid preventive therapy (IPT) should be considered for people living with HIV (PWH) to reduce the incidence of active TB 1. (Evidence: Strong)
The use of IPT in PWH did not significantly increase the risk of peripheral neuropathy or hepatotoxicity 1. (Evidence: Strong)
IPT did not show a significant reduction in all-cause mortality in PWH 1. (Evidence: Strong)References
1 Jagi JL, Thomas C, Gudi SK, Undela K. Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV. AIDS (London, England) 2023. link